Extracellular Vesicles From Prevotella
AssigneeEvelo Biosciences, Inc.
InventorsBrian Goodman, Baundauna Bose, Christopher J. H. Davitt, Sofia M. R. Carlton, Will Caffry, Hank Wu
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions related to Prevotella EVs useful as therapeutic agents.
Claims47
A pharmaceutical composition comprising isolated Prevotella bacterial extracellular vesicles (EVs).
A pharmaceutical composition comprising Prevotella bacterial extracellular vesicles (EVs) and Prevotella bacteria.
3-8. (canceled)
A pharmaceutical composition comprising Prevotella bacteria isolated from EVs.
(canceled)
15-16. (canceled)
18-19. (canceled)
24-70. (canceled)
72-73. (canceled)
75-78. (canceled)
80-81. (canceled)
The method of claim 76, wherein the disease is an autoimmune disease, an inflammatory disease, a metabolic disease, or a cancer.
84-89. (canceled)
92-94. (canceled)
101-115. (canceled)
117-122. (canceled)
124-131. (canceled)
A method of generating an engineered Prevotella bacterium comprising introducing into the Prevotella bacterium a modification that results in the increased production of EVs.
133-141. (canceled)
A method of generating an engineered Prevotella bacterium comprising introducing into the Prevotella bacterium a modification that results the production of EVs with an improved therapeutic property by the Prevotella bacterium.
143-158. (canceled)
A method of culturing a Prevotella bacterium for improved EV production, the method comprising growing the Prevotella bacteria under stress-inducing growth conditions.
161-181. (canceled)
Dependencies are inferred from the claim text.